Tulsa, Ok (PRWEB) August 22, 2012
Tulsa personal injury attorney Jeff Martin says his law firm is reviewing potential GranuFlo injury cases, which may include kidney dialysis patients who have suffered cardiac arrest related to the product.
According to a New York Times report, the Food and Drug Administration (FDA) is investigating Fresenius Medical Care, a German company that provides treatments in its dialysis centers to approximately one-third of the estimated 400,000 dialysis patients in the country. One of its products, a dialysis drug known as GranuFlo, has been linked to drastically increased rates of cardiac arrest in patients who have taken it, the Times reports.
According to the news story, dated June 14, 2012, FMC is a leading supplier of medical equipment and drugs used by kidney patients and is being investigated by the FDA for having failed to explain potential GranuFlo heart risks to dialysis patients.
Dialysis is a process that replaces the kidneys’ key function in removing toxic waste from the blood system. This process requires bicarbonate, an alkaline substance, to neutralize acid that can build up in the blood. GranuFlo contains an ingredient that is converted by the patient’s body into bicarbonate, but it contains more bicarbonate than other brands of the drug on the market, according to The Times article. Not all doctors figure in the higher amount that GranuFlo contains when prescribing additional bicarbonate to patients, which can result in dangerous drug heart problems including a GranuFlo death, The Times reports.
The Times article states that last November Fresenius’s medical office sent an internal memo to physicians practicing in the company’s dialysis centers. The letter warned the doctors that improper use one of GranuFlo appeared to be contributing to steep rise in the risk of patients suffering cardiac arrest fatalities.
Cardiac arrest occurs when the hearts stops pumping, putting some dialysis patients in danger of suffering a GranuFlo fatal injury, according to The Times. Despite FMC’s internal memo regarding the potentially hazardous dialysis drug, GranuFlo cardiac arrest warnings were not conveyed to patients in the company’s dialysis centers, The Times article states. Dialysis centers owned by other companies but which administer GranuFlo to its patients also were uninformed of bicarbonate overdose GranuFlo risks, according to the article.
Dr. Thomas F. Parker III, chief medical officer at Renal Ventures, a dialysis chain using Fresenius products, was quoted in The Times’ story, attesting that, “If the data was sufficient to warn their doctors, then all users of the product should have been made aware of it.”
Personal injury attorney Jeff Martin concurs. “It is incumbent upon dangerous drug manufacturers to inform patients, first and foremost, of risks associated with potentially deadly medications,” said Martin. “Thousands of dialysis patients could be in danger of a GranuFlo fatality but are unaware of their GranuFlo prescription risks.”
The FDA may issue a formal warning to Fresenius if it decides that the company should have alerted kidney dialysis GranuFlo patients and other dialysis centers of the potentially dangerous GranuFlo bicarbonate levels, according to The Times article.
Anyone who has experienced a GranuFlo cardiac arrest or lost a loved one due to GranuFlo death may call 1-900-980-9205 or go to http://www.jeffmartinlaw.com for more information.
About the Law Offices of Jeff Martin
Jeff Martin has been a personal injury attorney in Tulsa, Oklahoma for over two decades. He and his colleagues at the Law Offices of Jeff Martin are known for aggressive, reliable representation and they have successfully sued big insurance companies and other corporations when clients’ personal injury cases could not be settled out of court.
The Law Offices of Jeff Martin
4815 S. Harvard, Suite# 380
Tulsa, OK 74135